Register

UC Irvine   

Questions discussed in this category

How would you approach therapy for a patient with newly diagnosed non-GC DLBCL with previous anthracycline exposure?
240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...
2 Answers available
In light of the TRIANGLE data at ASH, how are you now approaching a transplant-eligible patient with a new diagnosis of aggressive mantle cell lymphoma?
Are you adding ibrutinib? Should we add ibrutinib to NORDIC? Still referring to transplant? 
2 Answers available
How would you approach therapy for a transplant-eligible patient with peripheral T cell lymphoma NOS who experiences early relapse after CHOEP, but achieves remission to salvage therapy?
Would you still go to auto or consider allo? 
1 Answer available
How would treat a patient with good performance status with PTCL-NOS found to have leptomeningeal disease during treatment course with CHOEP?
Would you intercalate HD-MTX with her CHOEP?
1 Answer available
How would you treat a patient with blastoid mantle cell lymphoma with hepatic involvement causing significantly elevated bilirubin?
1 Answer available
What is the optimal treatment for a fit, elderly patient with NGC diffuse large B cell lymphoma that recurred about 1 year after dose-attenuated R-CHOP?
1 Answer available
How would you approach therapy for newly diagnosed germinal-center DLBCL who previously received an unknown systemic regimen with radiation for history of Hodgkin Lymphoma?
Would you give R-CHOP without knowing if there was use of prior anthracycline? 
1 Answer available


Papers discussed in this category

Eur J Haematol, 2023 Mar 27
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
Ann Oncol, 2009 Jul 01
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Blood, 2010 Jul 21
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
N Engl J Med, 2022 Jun 03
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
J Hematol Oncol, 2021 Oct 30
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.

Related Topics

Copyright © 2023 theMednet
All Rights Reserved.